AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

5,155.00p
   
  • Change Today:
      28.00p
  • 52 Week High: 5,508.00
  • 52 Week Low: 4,007.00
  • Currency: UK Pounds
  • Shares Issued: 1,265.91m
  • Volume: 2,029,967
  • Market Cap: 65,258m
  • RiskGrade: 137

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (16-10-2017)

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 4.1% 4.1%
Div Cover 1.5 1.3
Op Mrgn 23.0% 26.0%
ROCE n/a  
Latest F'cast
P/E 15.9 18.0
PEG 13.5 n/a
Pr/Revenue 4.1 3.9
Pr/Book 5.2  
Latest F'cast
Revenue -9.8% -41.3%
PBT 15.7% -8.4%
EPS 1.2% -11.8%
DPS n/a -42.6%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 27,973.00 7,646.00 683.00¢ 5.6 n/a -6% 280.00¢ 7.3%
31-Dec-13 25,711.00 3,267.00 505.00¢ 9.4 n/a -26% 280.00¢ 5.9%
31-Dec-14 26,095.00 1,246.00 428.00¢ 14.1 n/a -15% 280.00¢ 4.6%
31-Dec-15 23,641.00 3,069.00 426.00¢ 14.3 n/a -0% 280.00¢ 4.6%
31-Dec-16 21,319.00 3,552.00 431.00¢ 13.6 13.6 +1% 280.00¢ 4.8%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 16,563.93 4,306.05 286.17p 18.0 n/a -12% 212.66p 4.1%
31-Dec-18 16,742.69 4,249.72 288.42p 17.9 22.8 +1% 215.11p 4.2%

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

FDA grants Tagrisso BTD for 1st-line EGFR nsclc 09-Oct-2017 07:00 RNS
Total Voting Rights 02-Oct-2017 15:00 RNS
Director/PDMR Shareholding 26-Sep-2017 12:00 RNS

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 5,155.00p
Change Today 28.00p
% Change 0.55 %
52 Week High 5,508.00
52 Week Low 4,007.00
Volume 2,029,967
Shares Issued 1,265.91m
Market Cap 65,258m
RiskGrade 137

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
60.83% below the market average60.83% below the market average60.83% below the market average60.83% below the market average60.83% below the market average
1.59% below the sector average1.59% below the sector average1.59% below the sector average1.59% below the sector average1.59% below the sector average
Price Trend
33.33% above the market average33.33% above the market average33.33% above the market average33.33% above the market average33.33% above the market average
31.25% above the sector average31.25% above the sector average31.25% above the sector average31.25% above the sector average31.25% above the sector average
Income
64.12% above the market average64.12% above the market average64.12% above the market average64.12% above the market average64.12% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Growth
49.76% below the market average49.76% below the market average49.76% below the market average49.76% below the market average49.76% below the market average
81.82% below the sector average81.82% below the sector average81.82% below the sector average81.82% below the sector average81.82% below the sector average

What The Brokers Say

Strong Buy 20
Buy 2
Neutral 14
Sell 1
Strong Sell 3
Total 40
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  Interim 2nd Interim
Ex-Div 10-Aug-17 16-Feb-17
Paid 11-Sep-17 20-Mar-17
Amount 90.00¢ 190.00¢

Trades for 16-Oct-2017

Time Volume / Share Price
17:06 806 @ 5,157.16p
17:06 806 @ 5,157.16p
17:06 81 @ 5,151.83p
17:06 81 @ 5,151.83p
17:05 313 @ 5,173.05p

Top of Page